Abbott

Abbott's Electromedical and Electrotherapeutic Apparatus Manufacturing operations reported approximately 973 million kg CO2e of Scope 1 and 2 emissions in 2024, with Scope 1 emissions totalling about 502 million kg CO2e and Scope 2 market-based emissions at approximately 393 million kg CO2e. Scope 3 emissions for 2024 were substantial, with purchased goods and services accounting for roughly 7.06 billion kg CO2e and upstream transportation and distribution contributing about 1.24 billion kg CO2e.

In 2023, Abbott reported Scope 1 emissions of approximately 504 million kg CO2e and Scope 2 market-based emissions of about 400 million kg CO2e.

Abbott is committed to reducing absolute Scope 1 and 2 greenhouse gas emissions by 30% by 2030, using 2018 as a baseline. This target aligns with the Science Based Targets initiative's (SBTi) objective of keeping global warming well below two degrees Celsius. Additionally, Abbott aims to achieve near-zero Scope 1 and 2 emissions by 2025. The company has also committed to a Net Zero emissions goal by 2050 for its UK subsidiary, Abbott Laboratories Ltd. A further commitment includes ensuring that 82% of its suppliers, covering purchased goods and services and upstream transportation and distribution, will have science-based targets by 2026.